氨磺必利与奥氮平治疗精神分裂症患者安全性比较

Compare safety of amisulpride and olanzapine in the treatment of first-episode schizophrenia.

ES评分 0

DOI
刊名
Journal of International Psychiatry
年,卷(期) 2016, 43(2)
作者
作者单位

芜湖市第四人民医院精神科 ;

摘要
目的 比较氨磺必利与奥氮平治疗首发精神分裂症的安全性。方法 对80例使用氨磺必利或奥氮平的精神分裂症患者病案资料回顾性调查分析,统计一般人口学资料、副反应、精神症状测评、实验室检查结果。结果 全部80例病例中,氨磺必利组(amisulpride group,AG)性激素异常25例,奥氮平组(olanzapine group,OG)18例,差异有统计学意义(χ2=4.220,P =0.40)。进一步研究发现AG组在血清泌乳素水平高于OG组[(63.12±38.74)ng/mL;(37.84±36.50)ng/mL];差异有统计学意义(t =-3.003,P =0.004)。AG组与OG组在一般人口学资料、副反应、精神症状测评等方面差异无统计学意义。结论 氨磺必利对治疗首发精神分裂症安全性与奥氮平相当,需注意氨磺必利对精神分裂症患者内分泌的影响。
Abstract
Objective To compare the different of safety in the treatment of first-episode schizophrenia betweenamisulpride and olanzapine. Methods A retrospective study was conducted 80 cases with first-episode schizophreniatreatment of amisulpride or olanzapine on the general demographic data、sidereaction、evaluationofpsychiatricsymptoms 、sidereaction、evaluationofpsychiatricsymptoms side reaction、evaluationofpsychiatricsymptoms 、evaluationofpsychiatricsymptoms evaluation of psychiatric symptomsand laboratory examination.Results All of 80 cases,Thenumberof abnormal sexhormoneswas25caseinamisulpride ,Thenumberof abnormal sexhormoneswas25caseinamisulpride The number of abnormal sex hormones was 25 case in amisulpridegroup,andwas18caseinolanzapinegroup.Thedifferencebetweentwogroupshavestatisticallysignificant(χ ,andwas18caseinolanzapinegroup.Thedifferencebetweentwogroupshavestatisticallysignificant(χ and was 18 case in olanzapine group.Thedifferencebetweentwogroupshavestatisticallysignificant(χ .Thedifferencebetweentwogroupshavestatisticallysignificant(χ The difference between two groups have statistically significant(χ (χ2=4.220,P =0.40). Further studiesconclusivelyshowedamisulpridegrouphadhigher level of serumPRLthanolanzapine ). Further studiesconclusivelyshowedamisulpridegrouphadhigher level of serumPRLthanolanzapine Further studies conclusively showed amisulpride group had higher level of serum PRL than olanzapinegroup[(63.12±38.74)ng/ml;(37.84±36.50)ng/ml]( [(63.12±38.74)ng/ml;(37.84±36.50)ng/ml]( 63.12±38.74)ng/ml;(37.84±36.50)ng/ml]( )ng/ml;(37.84±36.50)ng/ml]( ng/ml;(37.84±36.50)ng/ml]( ;(37.84±36.50)ng/ml]( 37.84±36.50)ng/ml]( )ng/ml]( ng/ml]( ](t =-3.003,P =0.004). Thedifferenceof thegeneral demo- ). Thedifferenceof thegeneral demo- The difference of the general demo-graphic data、sidereaction、evaluationof psychiatricsymptomsbetweenmisulpridegroupandolanzapinegroupwerenot 、sidereaction、evaluationof psychiatricsymptomsbetweenmisulpridegroupandolanzapinegroupwerenot side reaction、evaluationof psychiatricsymptomsbetweenmisulpridegroupandolanzapinegroupwerenot 、evaluationof psychiatricsymptomsbetweenmisulpridegroupandolanzapinegroupwerenot evaluation of psychiatric symptoms between misulpride group and olanzapine group were notsignificant(P >0.05). ). Conclusion The safety of amisulpride on first-episode schizophrenia is equivalent with olanzapine.We should pay attention to the influence of endocrine of the amisulpride therapy schizophrenia patients.【Keywords】 Key words】Amisulpride;Olanzapine;Schizophrenia; ;Olanzapine;Schizophrenia; Olanzapine;Schizophrenia; ;Schizophrenia; Schizophrenia;
关键词
氨磺必利;奥氮平;精神分裂症;
KeyWord
Amisulpride;Olanzapine;Schizophrenia; ;
基金项目
页码 279-281
  • 参考文献
  • 相关文献
  • 引用本文

朱文礼*,王 伟,王继轩,储贝贝,杨永春,程万良. 氨磺必利与奥氮平治疗精神分裂症患者安全性比较 [J]. 国际精神病学杂志. 2016; 43; (2). 279 - 281.

  • 文献评论

相关学者

相关机构